Ashmore shares priced for too much recovery, says Cavendish

Cavendish reiterated its sell rating on Ashmore Group, arguing the shares already price in a substantial recovery in client flows and assets under management. The broker reduced its adjusted EBITDA forecasts for 2027 and 2028 by roughly 10%, reflecting management guidance for higher variable remuneration tied to seed-capital portfolio gains.

Analysis

The key issue is not the absolute remuneration increase but the operating-leverage asymmetry it exposes: seed-capital gains can lift reported investment income while variable compensation absorbs a meaningful portion of the upside. That reduces the conversion of a cyclical EM recovery into durable EBITDA-margin expansion, making a premium valuation harder to defend versus more diversified listed asset managers. If flows recover but compensation remains structurally more variable, ASHM may deliver AUM growth without the EPS torque investors are underwriting.

Near term, ASHM is vulnerable to earnings-estimate drift rather than a single binary catalyst. Quarterly AUM/flow disclosures over the next 1-3 months need to exceed both EM-beta-driven market appreciation and implied net-flow expectations; asset-market gains alone will not validate the recovery thesis. A stronger dollar, renewed EM sovereign-credit stress, or China-related risk aversion would create a double hit through lower AUM and weaker performance-fee/seed-book economics.

The contrarian case is that seed portfolio gains are economically real and signal an improving opportunity set, while a broad EM risk-on regime could rapidly re-rate the shares despite lower margin estimates. That requires sustained positive net flows, not merely investment performance: monitor net new money, annualized compensation-to-revenue ratio, and management’s medium-term margin commentary. Without evidence of flow acceleration, the market is likely to de-rate ASHM toward a lower multiple as FY27/FY28 consensus catches down.

Key Decisions for Investors

• Maintain or initiate a 3-6 month short ASHM only on a relief rally following its next AUM update; target a 10-15% downside from entry as forward EBITDA estimates adjust lower. Cover if reported net inflows turn decisively positive for two consecutive reporting periods and compensation/revenue guidance remains contained.
• Use a relative-value expression: long Schroders (SDR) / short ASHM over 6 months, sized beta-neutral. SDR offers greater product and client diversification, while ASHM has higher sensitivity to EM fund-flow reversals and margin disappointment; exit if EM dedicated-fund flows accelerate broadly rather than selectively.
• Do not treat seed-capital gains as recurring operating earnings in valuation work. Set an alert for any increase in recurring management-fee revenue or a compensation ratio that fails to rise with seed gains; either development would weaken the short thesis.
• For long-only exposure, defer purchases until the next disclosure demonstrates net inflows rather than market-led AUM growth. A credible entry signal is positive flows alongside stable or improving operating-margin guidance; absent that, recovery expectations appear insufficiently compensated.